Catheter Precision secures up to $36.5M in institutional financing

Catheter Precision (VTAK) has agreed to the termination of its at-the-market equity offering program and has completed a strategic financing transaction with institutional investors for up to $36.5M to support accelerated growth. Key Highlights: ATM equity program to be terminated. No future equity lines of credit or forward-priced agreements are anticipated. Strategic institutional capital secured to fund expansion. Balance sheet and liquidity significantly strengthened. The company’s short-term notes have been converted to long term by extending maturities out to two and three years. Additional short and long-term liabilities of approximately $9M on the 9/30/25 balance sheet are being converted into equity.